MannKind (MNKD) Stock Continues Decline Today

NEW YORK (TheStreet) -- MannKind  (MNKD) continued its decline Friday after news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device.

MannKind's own inhaled insulin device, Afrezza, has been the subject of much coverage recently with an FDA decision upcoming. An FDA advisory panel issued a positive recommendation on Afrezza last week.

MannKind dropped 7.01% to $6.37 at 3:18 p.m., at which point more than 11.5 million shares had changed hands, greater than the average volume of 10,426,300.

For much more on Dance Biopharm, be sure to read TheStreet's Adam Feuerstein's article here.

Must Read: MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MNKD Chart

MNKD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Tesla Jumps on Model 3 Expansion Hopes, China Trade Truce

Tesla Jumps on Model 3 Expansion Hopes, China Trade Truce

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO